Ringhand P, Maxon H R, Ritschel W A, Chen I W, Bauman D H
J Clin Pharmacol. 1980 Feb-Mar;20(2-3):91-7. doi: 10.1002/j.1552-4604.1980.tb02530.x.
In vitro dissolution profile testing of 12 generic 6-propyl-2-thiouracil (PTU) formulations indicated significant differences in their solubilities in water and in 0.1N hydrochloric acid. Two products, representing the extremes of solubility, were subsequently tested for bioavailability. Bioavailability data from euthyroid, hyperthyroid, and hypothyroid beagle dogs indicated that the rate of PTU absorption varied appreciably between the two generic products studied. These results were consistent with the in vitro dissolution data. Comparisons of the pharmacokinetic parameters obtained for the euthyroid beagle dog to those reported for euthyroid man12 indicated that the beagle dog is an adequate model for PTU disposition in man. These combined results suggest that all generic formulations of PTU are not the same and that the most soluble product may be desirable in situations where rapid absorption is important, such as thyroid storm.
12种通用型6-丙基-2-硫氧嘧啶(PTU)制剂的体外溶出度曲线测试表明,它们在水和0.1N盐酸中的溶解度存在显著差异。随后对两种代表溶解度极值的产品进行了生物利用度测试。来自正常甲状腺、甲状腺功能亢进和甲状腺功能减退的比格犬的生物利用度数据表明,在所研究的两种通用产品之间,PTU的吸收速率有明显差异。这些结果与体外溶出数据一致。将正常甲状腺比格犬获得的药代动力学参数与正常甲状腺人类报告的参数进行比较表明,比格犬是人类PTU处置的合适模型。这些综合结果表明,PTU的所有通用制剂并不相同,在快速吸收很重要的情况下,如甲状腺危象,最易溶的产品可能是理想的。